Dublin, Jan. 04, 2022 (GLOBE NEWSWIRE) -- The "Global Cancer Diagnostics Partnering Terms and Agreements 2014-2021" report has been added to ResearchAndMarkets.com's offering.
The Global Cancer Diagnostics Partnering Terms and Agreements 2014-2021 report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.
This report provides details of the latest Cancer Diagnostics agreements announced in the life sciences since 2014.
The report takes the reader through a comprehensive review Cancer Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Cancer Diagnostics partnering deals.
The report presents financial deal term values for Cancer Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the Cancer Diagnostics partnering field; both the leading deal values and most active Cancer Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 1100 online deal records of actual Cancer Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
A comprehensive series of appendices is provided organized by Cancer Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Cancer Diagnostics partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cancer Diagnostics technologies and products.
Key benefits
Global Cancer Diagnostics Partnering Terms and Agreements 2014-2021 provides the reader with the following key benefits:
- In-depth understanding of Cancer Diagnostics deal trends since 2014
- Access to headline, upfront, milestone and royalty data
- Detailed access to actual Cancer Diagnostics contracts entered into by leading biopharma companies
- Identify most active Cancer Diagnostics dealmakers since 2014
- Insight into terms included in a Cancer Diagnostics partnering agreement, with real world examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope
Cancer Diagnostics Partnering Terms and Agreements includes:
- Trends in Cancer Diagnostics dealmaking in the biopharma industry since 2014
- Access to headline, upfront, milestone and royalty data
- Access to Cancer Diagnostics contract documents
- Leading Cancer Diagnostics deals by value since 2014
- Most active Cancer Diagnostics dealmakers since 2014
In Global Cancer Diagnostics Partnering Terms and Agreements 2014-2021, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
- Technology type
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Cancer Diagnostics dealmaking
2.1. Introduction
2.2. Cancer Diagnostics partnering over the years
2.3. Most active Cancer Diagnostics dealmakers
2.4. Cancer Diagnostics partnering by deal type
2.5. Cancer Diagnostics partnering by therapy area
2.6. Deal terms for Cancer Diagnostics partnering
2.6.1 Cancer Diagnostics partnering headline values
2.6.2 Cancer Diagnostics deal upfront payments
2.6.3 Cancer Diagnostics deal milestone payments
2.6.4 Cancer Diagnostics royalty rates
Chapter 3 - Leading Cancer Diagnostics deals
3.1. Introduction
3.2. Top Cancer Diagnostics deals by value
Chapter 4 - Most active Cancer Diagnostics dealmakers
4.1. Introduction
4.2. Most active Cancer Diagnostics dealmakers
4.3. Most active Cancer Diagnostics partnering company profiles
Chapter 5 - Cancer Diagnostics contracts dealmaking directory
5.1. Introduction
5.2. Cancer Diagnostics contracts dealmaking directory
Chapter 6 - Cancer Diagnostics dealmaking by technology type
Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendices
Appendix 1 - Cancer Diagnostics deals by company A-Z
Appendix 2 - Cancer Diagnostics deals by stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
Appendix 3 - Cancer Diagnostics deals by deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty
Appendix 4 - Cancer Diagnostics deals by therapy area
Appendix 5 -Deal type definitions
For more information about this report visit https://www.researchandmarkets.com/r/62dghn
